2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
|
|
- Amie Page
- 1 years ago
- Views:
Transcription
1 PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November Purpose of Application To seek an Authority Required listing for initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in a patient with a WHO status of 2 or less, who has failed treatment with sunitinib. 2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma. At the November 2009 meeting, the PBAC rejected a submission for everolimus for treatment, as the sole PBS-subsidised therapy, of a patient with Stage IV clear cell variant renal cell carcinoma after failure of treatment with sorafenib or sunitinib on the basis of uncertain clinical benefit and a high and uncertain cost-effectiveness ratio. For full details, see November At its July 2010 meeting, the PBAC rejected a re-submission on the basis of uncertain clinical benefit and a high and uncertain cost-effectiveness ratio. For full details, see July At the November 2010 meeting, the PBAC rejected a minor re-submission on the basis of a high and uncertain cost-effectiveness ratio. The PBAC considered that despite the clinical need and trial-based evidence of improved PFS, the magnitude of the clinical benefit in relation to survival was uncertain and that with plausible survival modelling, the ICER remained unacceptably high. 3. Registration Status Everolimus tablets 5 mg and 10 mg were registered by the TGA on 29 July 2009 for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. 4. Listing Requested and PBAC s View Authority Required Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has failed treatment with sunitinib and has a WHO status of 2 or less. Failure of treatment with sunitinib is defined as: (i) Progressive disease as defined by the RECIST criteria; or (ii) Toxicity that is sunitinib related and necessitates permanent cessation of sunitinib. Page 1 of 5
2 Stable disease (SD) is small changes that do not meet above criteria. Authority Required Continuing treatment beyond 3 months, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) in a patient who has previously been issued with an authority prescription for everolimus and who has stable or responding disease according to the RECIST criteria. Stable disease (SD) is small changes that do not meet above criteria. Authority Required (grandfather) Initial treatment, as the sole PBS-subsidised therapy, of Stage IV clear cell variant renal cell carcinoma (RCC) after failure of treatment with sunitinib in a patient who was receiving treatment with everolimus prior to (insert LISTING DATE). Failure of treatment with sunitinib is defined as: (i) Progressive disease as defined by the RECIST criteria; or (ii) Toxicity that is sunitinib related and necessitates permanent cessation of sunitinib. Stable disease (SD) is small changes that do not meet above criteria. For PBAC s view, see Recommendation and Reasons. 5. Clinical Place for the Proposed Therapy Renal cell carcinoma (RCC) is a form of kidney cancer that arises from the cells of the renal tubule. The management and prognosis of a patient with RCC is determined by the stage of the disease. Surgery is the only curative treatment option for localised RCC radical nephrectomy is considered the gold-standard treatment for all patients with localised tumours. In patients with locally advanced or metastatic disease, nephrectomy may also be considered. As RCC progresses, the tumour grows and enlarges, and often spreads to adjacent organs. However, most patients are diagnosed with advanced RCC which is often refractory to treatment and associated with a poor prognosis. Currently, only sunitinib is PBS listed for this indication. The submission proposed that everolimus would be a new treatment option for patients with advanced RCC who have failed sunitinib. Page 2 of 5
3 6. Comparator Best supportive care (BSC) was nominated as the comparator. This was previously considered appropriate by the PBAC. 7. Clinical Trials No changes had been made to the trial data previously presented from the RECORD-1 trial, a randomised trial comparing everolimus, 10 mg per day orally, with placebo in patients with metastatic clear cell carcinoma (mrcc) with Karnofsky performance score of at least 70 and previous progression on, or within six months of treatment with, sunitinib and/or sorafenib. The primary clinical outcome was progression-free survival (PFS), and patients in the placebo arm could cross-over to everolimus after progression. One additional publication (Motzer et al 2010) arising from the RECORD-1 trial was identified in an updated literature search, see below: Trial ID/ First Protocol title/ Publication title author Direct randomised trial(s) RECORD-1 Motzer R et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma. Final results and analysis of prognostic factors. Publication citation Cancer 2010; 116 (18): Results of Trials The PBAC recalled that everolimus demonstrated a statistically significant improvement in progression-free survival (PFS) (HR: 0.33, 95% CI: 0.25, 0.43) compared with placebo but the extent of the benefit, three months, was small. The overall survival (OS) data for the intention-to-treat population demonstrated no statistically significant difference for everolimus compared with placebo, with a hazard ratio 0.87 (95% CI: ). As previously noted, this result was biased towards no treatment effect because the RCT was designed to allow for switching to everolimus on progression. That is, the result for OS is confounded by the extensive (77%) cross-over of placebo patients to everolimus at progression. The PBAC also noted that the RECORD-1 trial did not demonstrate a statistically significant benefit for everolimus compared with placebo in terms of other secondary outcomes, including quality of life. However, these results are also confounded by the extensive (77%) cross-over of placebo patients to everolimus at progression. No new toxicity data were presented in the re-submission and the safety assessment of the RECORD-1 trial had not been updated. 9. Clinical Claim The re-submission claimed everolimus has superior efficacy and inferior safety in mrcc compared with placebo. The PBAC considered that the main uncertainty was whether there is a survival gain associated with treatment with everolimus and if so, the magnitude of the gain. The PBAC Page 3 of 5
4 noted that the clinical importance of the PFS gain had not been demonstrated in terms of improvements in the symptoms of RCC. The PBAC had previously considered that the re-submission s claim of inferior safety of everolimus compared with placebo was reasonable. 10. Economic Analysis An updated modelled economic evaluation was presented. The submission presented additional UK historical control survival data and a revised extrapolation method to derive overall survival curves for the placebo arm to be used in the modelled economic evaluation. The base case ICER (time horizon 5 years) using the Rank Preserving Structural Failure Time method (RPSFT) was calculated to be between $45,000 - $75,000 per QALY. For PBAC s view, see Recommendation and Reasons. 11. Estimated PBS Usage and Financial Implications The likely number of patients treated was estimated by the submission to be less than 10,000 over the first 5 years. The estimation was considered uncertain due to uncertainty in the projected sunitinib patient numbers and uncertainty in the proportion of sunitinib patients eligible for everolimus. The net financial cost to the PBS was estimated by the submission to be less than $10 million in Year 5. The estimation was considered uncertain. 12. Recommendation and Reasons The PBAC noted it had previously accepted that BSC was the appropriate comparator. The PBAC recalled that in July 2010 there was uncertainty about a conclusion of superior efficacy in mrcc with everolimus compared with placebo based on the benefit in terms of PFS, when no benefit in terms of OS or quality of life was observed in RECORD-1. Based on the supporting data the claim for inferior safety was considered reasonable. The PBAC noted there were no new trial data provided in the re-submission. However, the submission presented additional UK historical control survival data and a revised extrapolation method to derive overall survival curves for the placebo arm to be used in the modelled economic evaluation. The results of this survival analysis were compared with community-based survival data sourced from Medicare on sunitinib patients, to further validate the UK data s applicability to the Australian population. There was also an update (in the manuscript form) of the systemic review by Delea et al to estimate the ratio of incremental OS benefit to incremental PFS. The PBAC noted that the sunitinib data show survival appears worse in the community than in the trial (Motzer et al 2010), highlighting that trial results may overestimate the benefit of therapy. The PBAC considered that these additional data had increased rather than decreased the uncertainty regarding survival by indicating that the time horizon of 5 years may be too optimistic. Page 4 of 5
5 The PBAC also noted that the study population for everolimus is a combination of failed TKIs (sunitinib) and patients who have never been exposed to an effective TKI (sorafenib). The PBAC has previously noted that sorafenib has failed to show any benefit as a first line agent in RCC, and hence this may have influenced the benefit observed for everolimus. The base case ICER (time horizon 5 years) using the RPSFT was calculated to be between $45,000 - $75,000 per QALY in the current re-submission. The PBAC noted the results of the sensitivity analyses indicate that the model is most sensitive to the model duration due to the relatively large proportion of the QALY gain extrapolated to occur beyond the duration of the trial. The PBAC noted that in calculating the ICERs there is an assumption that treatment would be ceased on progression, which may not happen in clinical practice as everolimus is administered orally. Also, clinicians may not routinely monitor patients with scans to detect progression at this stage of the disease. Therefore, the PBAC considered that the ICERs could potentially be higher. The PBAC accepted that there is a high clinical need for alternative therapies for renal cancer. However, the main uncertainty for the PBAC is whether there is a survival gain associated with this drug and if so, the magnitude of the gain. The PBAC noted that the clinical importance of the PFS gain has not been demonstrated in terms of improvements in the symptoms of RCC. Therefore, the PBAC rejected the submission on the basis of a high and uncertain costeffectiveness ratio. The PBAC acknowledged and noted the consumer comments on this item. Recommendation: Reject 13. Context for Decision The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision. 14. Sponsor s Comment The sponsor has no comment. Page 5 of 5
The role of mtor inhibitors in renal cancer. Tom Powles Professor of Urology Cancer at Barts Cancer Institute Director of Cancer Barts Cancer Centre
The role of mtor inhibitors in renal cancer. Tom Powles Professor of Urology Cancer at Barts Cancer Institute Director of Cancer Barts Cancer Centre disclosures Novartis Pfizer Merck BMS Roche AZ PI3K
2. Background This indication of rivaroxaban had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the
The submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
2. Background This drug had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Ambrisentan, tablets, 5 mg and 10 mg, Volibris Sponsor: GlaxoSmithKline Australia Pty Ltd Date of PBAC Consideration: July 2009 1. Purpose of Application The submission
Case study 1 Afinitor and Renal Cell Carcinoma*
* Summary Need Novartis. This suggests that the company saw some benefit to moving out of this categorisation. Afinitor can prolong the time to disease progression and survival for patients with renal
The NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
Social Values and Health Priority Setting Case Study
Social Values and Health Priority Setting Case Study Title of Case Study Author Author Contact Sunitinib as a first line treatment for advanced and/or metastatic renal cell carcinoma Sarah Clark s.l.clark@ucl.ac.uk
Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
Axitinib as an option for second line advanced renal cell carcinoma with progression after tyrosine kinase inhibitor (or other first-line therapy)
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Axitinib as an option for second line advanced renal cell carcinoma with progression after tyrosine kinase inhibitor Axitinib as an option for second line advanced
Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
Timing of TKI s pre- or post-nephrectomy
Timing of TKI s pre- or post-nephrectomy Dr Simon Crabb Senior Lecturer and Honorary Consultant in Medical Oncology Cancer Sciences Unit, University of Southampton Faculty of Medicine Initial nephrectomy
EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also deliberated on the alignment of bendamustine with patient values. perc noted that bendamustine has a progression-free survival advantage, may be less toxic than currently available therapies
pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013
pan-canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for Multiple Myeloma October 22, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
Guidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma
Issue date: June 2011 Rituximab for the first-line maintenance treatment of follicular non-hodgkin s lymphoma This guidance was developed using the the single technology appraisal process NICE technology
CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR)
CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA: RESULTS OF A RANDOMISED PHASE III TRIAL (METEOR) This late-breaking abstract was presented on 26 th September 215 in Presidential
Case study 4 Revlimid and Multiple Myeloma*... Payer approval ...
* Summary Need Revlimid brings benefits to myeloma patients, by slowing disease progressing and lengthening patients lives. Myeloma affects 1.3 in every 10,000 people. In the UK just under 5,000 people
Summary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma. Cytoreductive Surgery
The Role Of Cytoreductive Surgery In The Era Of Targeted Therapy For Metastatic Renal Cell Carcinoma Robert A. Figlin MD., FACP Acting Director City of Hope Comprehensive Cancer Center Cytoreductive Surgery
BNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
DOI: 10.3310/hta13suppl3/08 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck J Greenhalgh,* A
Stage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
Teriflunomide for treating relapsing remitting multiple sclerosis
Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation
Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche
Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche Andrea Busolo U.O. di Radiologia Rocco De Vivo U.O. di Oncologia Medica ULSS 6 - Vicenza Activity and efficacy
Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
Clinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395
Ceritinib for previously treated anaplastic lymphoma kinase positive non- small-cell lung cancer Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta395 NICE 2016. All rights reserved.
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED
ASX ANNOUNCEMENT 3 August 2011 ABN 53 075 582 740 BNC105 CANCER CLINICAL TRIALS REACH KEY MILESTONES CLINICAL PROGRAM TO BE EXPANDED Data from renal cancer trial supports progression of the trial: o Combination
If several different trials are mentioned in one publication, the data of each should be extracted in a separate data extraction form.
General Remarks This template of a data extraction form is intended to help you to start developing your own data extraction form, it certainly has to be adapted to your specific question. Delete unnecessary
2. Background The combined presentation of calcipotriol and betamethasone dipropionate had not previously been considered by the PBAC.
PUBLIC SUMMARY DOCUMENT Product: Calcipotriol with betamethasone dipropionate, ointment, 50 micrograms- 500 micrograms (base) per g, Daivobet Sponsor: CSL Biotherapies Limited Date of PBAC Consideration:
Dimethyl fumarate for treating relapsing remitting multiple sclerosis
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Dimethyl fumarate for treating relapsing remitting multiple sclerosis This guidance was developed using the single technology
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
DOI: 10.3310/hta13suppl1/08 Health Technology Assessment 2009; Vol. 13: Suppl. 1 Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck S Griffin,*
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer Issued: November 2010 guidance.nice.org.uk/ta208 NICE has accredited the process used by the Centre for Health Technology Evaluation
1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
Summary. Our position
Cancer Research UK response to NICE s consultation on the Appraisal Consultation Document: Bevacizumab, sorafenib, sunitinib and temsirolimus for the treatment of advanced and/or metastatic renal cell
Dimethyl fumarate for treating relapsing-remitting multiple sclerosis
Dimethyl fumarate for treating relapsing-remitting multiple Issued: August 2014 guidance.nice.org.uk/ta320 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to
Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
Technology appraisal guidance Published: 22 November 2006 nice.org.uk/guidance/ta112
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor- positive breast cancer Technology appraisal guidance Published: 22 November 2006 nice.org.uk/guidance/ta112 NICE 2006. All rights
PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
NICE s Appraisal of Cancer Medications: Recent Policy and Methodological Challenges
NICE s Appraisal of Cancer Medications: Recent Policy and Methodological Challenges Mark Sculpher, PhD Professor of Health Economics Centre of Health Economics University of York, UK Fred Hutchinson Cancer
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta
Tumori rari del rene: trattamento per stadio ed istologia Dr. Camillo Porta S.C. di Oncologia Medica, Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia Non-Clear Cell Renal Cell Carcinoma (nccrcc) nccrcc
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used
Version History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
perc also considered patient-reported outcomes of symptom burden and impact of treatment on symptom change or stability to be similar between trabectedin and dacarbazine up to cycle 8 in the SAR- 3007
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
Version History. Previous Versions. Drugs for MS.Drug facts box fampridine Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fampridine Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary Issued: July 2012 guidance.nice.org.uk/ta NICE has accredited the process used by the
Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
See rivaroxaban s March 2012 Public Summary Document relating to stroke and systemic embolism for further information.
PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15 mg and 20 mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: November 2012 1. Purpose of Application The resubmission sought
The trial and tribulations of predictive biomarkers in metastatic RCC.
The trial and tribulations of predictive biomarkers in metastatic RCC. Professor Thomas Powles Renal cancer lead for London Cancer Barts Cancer Institute and Royal Free Hospital UCL and QMUL. Proportion
National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
Lapatinib for the treatment of advanced and metastatic breast cancer: a review of the response to the ACD provided by the manufacturer of Lapatinib
Lapatinib for the treatment of advanced and metastatic breast cancer: a review of the response to the ACD provided by the manufacturer of Lapatinib 7 September 2008 Report by the NICE Decision Support
Patient Reported Outcomes in Ovarian Cancer Clinical Trials - Missed Opportunities and Lessons Learned
Patient Reported Outcomes in Ovarian Cancer Clinical Trials - Missed Opportunities and Lessons Learned Michael Friedlander 1, Rebecca Mercieca-Bebber 2,3 and Madeleine King 2,3 1.Director of Research ANZGOG
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application
Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma Technology appraisal guidance Published: 27 June 2007 nice.org.uk/guidance/ta121 NICE 2007. All rights reserved.
National Institute for Health and Care Excellence. Single Technology Appraisal (STA)
Single Technology Appraisal (STA) Eluxadoline for treating irritable bowel syndrome with diarrhoea Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please
Sorafenib. Bernard ESCUDIER Institut Gustave Roussy Villejuif, France
Sorafenib for renal cell carcinoma Bernard ESCUDIER Institut Gustave Roussy Villejuif, France Renal Cell Carcinoma: Drugs and Targets pvhl = HIFα CCI-779 Bevacizumab VEGF KDR PDGF PDGFR TGFα EGFR Sunitinib,
Cancer Drug Reimbursement within the Context of Clinical Trials. (Draft for consultation purposes) Version 8.0
Cancer Drug Reimbursement within the Context of Clinical Trials (Draft for consultation purposes) Version 8.0 May 17, 2013 Introduction Clinical and cost-effectiveness factors have led most public payers
How valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer
Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer Susan Honig, M.D. Patricia Cortazar, M.D. Rajeshwari Sridhara, Ph.D. Acknowledgements John Johnson Alison Martin Grant
A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva
A Randomized Placebo Controlled Study of Erlotinib (OSI-774, Tarceva ) ) versus Placebo in Patients with Incurable Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic
Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2228475/ Avastin (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Description: Avastin (Renal Cell Carcinoma) Analysis and
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation Issued: May 2012 guidance.nice.org.uk/ta256 NICE has accredited the process used by the Centre for Health
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper
Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society
Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer
Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Options for Endpoints First-Line Trials in Advanced OVCA Overall Survival:
Natalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis
Natalizumab for the treatment of adults with highly active relapsing remitting multiple sclerosis Premeeting briefing This briefing presents major issues arising from the manufacturer s submission, Evidence
Scottish Medicines Consortium. erdosteine 300mg capsules (Erdotin ) No. (415/07) Edmond Pharma Sr.l/Galen Ltd. 5 October 2007
Scottish Medicines Consortium erdosteine 300mg capsules (Erdotin ) No. (415/07) Edmond Pharma Sr.l/Galen Ltd. 5 October 2007 The Scottish Medicines Consortium has completed its assessment of the above
National Cancer Institute
National Cancer Institute Taking Part in Cancer Treatment Research Studies U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Taking Part in Cancer Treatment Research Studies If
Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243
Rituximab for the first-line treatment of stage III-IV follicular lymphoma Technology appraisal guidance Published: 25 January 2012 nice.org.uk/guidance/ta243 NICE 2012. All rights reserved. Your responsibility
Nalmefene for reducing alcohol consumption in people with alcohol dependence
Nalmefene for reducing alcohol consumption in people with alcohol dependence Issued: November 2014 guidance.nice.org.uk/ta325 NICE has accredited the process used by the Centre for Health Technology Evaluation
TAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
Denosumab for the prevention of skeletalrelated events in adults with bone metastases from solid tumours
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE National Institute for Health and Clinical Excellence Page 1 of 62 Final appraisal determination Denosumab for the prevention of skeletalrelated events
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
Daclatasvir for treating chronic hepatitis C
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Appraisal consultation document Daclatasvir for treating chronic hepatitis C The Department of Health has asked the National Institute for Health and Care
Endpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta376
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta376 NICE 2016. All rights reserved.
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Chapter 3. Affordable access assessing cost effectiveness
Chapter 3 Affordable access assessing cost effectiveness 3.1 As noted in Chapter 1, the Australian Government, like most governments in developed countries, provides subsidised patient access to medicines.
Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta377
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta377 NICE 2016. All
Feedback on the perc Initial Recommendation indicated that the manufacturer and patient advocacy groups, agreed with the Initial Recommendation.
perc reviewed patient advocacy group input indicating that patients value treatments that delay progression, relieve cancer-related symptoms, and improve QoL. Input indicated that patients with ER+/HER2
Bortezomib for the treatment of multiple myeloma patients
DOI: 1.331/hta13suppl1/5 Health Technology Assessment 29; Vol. 13: Suppl. 1 Bortezomib for the treatment of multiple myeloma patients C Green, J Bryant,* A Takeda, K Cooper, A Clegg, A Smith and M Stephens
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd
boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the
Adalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
Designing Economic Evaluations in Clinical Trials
Designing Economic Evaluations in Clinical Trials Henry Glick Institutt for helseledelse og helseøkonomi November 24, 2008 Good Value for the Cost Economic data collected as primary or secondary endpoints
Randomized trials versus observational studies
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James